ADVL0816: A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination with Vincristine/ Doxorubicin/Dexrazoxane, in Children with Relapsed/Refractory Solid Tumors or Leukemia- Conditions:
Adult Studies,
Cancer - Brain and Spinal Tumors,
Cancer - Leukemia and Lymphoma,
Medications
- Gender:
Female,
Male
Primary Estimate the maximum-tolerated dose and/or recommended phase II dose of obatoclax mesylate in combination with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride in pediatric patients with refractory solid tumors Define and describe the toxicities of obatoclax mes...
More
AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND #58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)- Conditions:
Adult Studies,
Cancer - Leukemia and Lymphoma,
Medications
- Gender:
Female,
Male
This phase II trial is studying the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma....
More
AALL0631: A Phase III Study of Risk Directed Therapy for Infants with ALL: Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431)/ Therapy for New Diagnosis Very High Risk Disease- Conditions:
Cancer - Leukemia and Lymphoma,
Medications
- Gender:
Female,
Male
PrimaryTo compare the 3-year event-free survival of infants with mixed lineage leukemia rearranged (MLL-R) acute lymphoblastic leukemia (ALL) randomized to treatment with a modified P9407 chemotherapy backbone with or without the FLT3 inhibitor lestaurtinib. Secondary1. To determine a safe, tolerab...
More
AAML05P1: Phase II Pilot Study of Killer Immunoglobulin-Like Receptor-Incompatible Unrelated Donor Hematopoietic Cell Transplantation in Young Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia/ Therapy for New Diagnosis High Risk Disease- Conditions:
Adult Studies,
Cancer - Leukemia and Lymphoma,
Medications
- Gender:
Female,
Male
1. To define the relationship between the status of donor NK-cell receptor and patient outcomes after killer immunoglobulin-like receptor-incompatible unrelated donor (URD) hematopoietic cell transplantation (HCT) in young patients with poor prognosis relapsed or refractory acute myeloid leukemia ...
More
AAML0631: Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox IND #103331) During Consolidation/ Therapy for New Diagnosis High Risk- Conditions:
Adult Studies,
Cancer - Leukemia and Lymphoma,
Medications
- Gender:
Female,
Male
Primary To decrease the total anthracycline dose from the best current published results in patients with standard-risk childhood acute promyelocytic leukemia (APL) while still maintaining a comparable event-free survival (EFS) Secondary To assign treatment based on risk stratification by WBC at di...
More
NCT00931931: A Phase I Dose Escalation Study of Intratumoral Herpes Simplex Virus-1 Mutant HSV1716 In Patients with Refractory Non-Central Nervous System (Non-CNS) Solid Tumors
Physician Friendly Version- Conditions:
Adult Studies,
Cancer - Leukemia and Lymphoma,
Vaccines
- Gender:
Female,
Male
Primary To determine whether intratumoral injection of HSV1716, at dose levels shown to be safe for adult tumors, is safe in adolescents and young adults with non-CNS solid tumors. Time Frame: Dose limiting toxicities will be assessed at 28 days after injection of HSV1716. Secondary To measure anti...
More
Clinical Study to Test Safety of a Virus Therapy in Children and Young Adults with Recurrent or Refractory Solid Tumors (Excluding Brain Tumors)
Family Friendly Version- Conditions:
Adult Studies,
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Cancer - Musculoskeletal Tumors,
Cancer - Neuroblastoma,
Cancer - Neurofibromatosis Tumors,
Cancer - Retinoblastoma,
Vaccines
- Gender:
Female,
Male
Cincinnati Children’s Hospital Medical Center is conducting a research study, sometimes known as a clinical trial or clinical study, to test how safe and well tolerated the study drug is in children and young adults with certain cancers. Researchers want to see what effects - good or bad - the stud...
More
ADVL0413: A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias- Conditions:
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. ...
More
ADVL0921: A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children With Recurrent / Refractory Solid Tumors and Leukemia- Conditions:
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Medications
- Gender:
Female,
Male
This phase II trial is studying the side effects of and how well Alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. ...
More
Study to Test Safety of a Virus Therapy Children / Young Adults- Conditions:
Adult Studies,
Cancer - Hemangioma and Vascular Malformation,
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Cancer - Musculoskeletal Tumors,
Cancer - Neurofibromatosis Tumors,
Medications,
Vaccines
- Gender:
Female,
Male
Cincinnati Children’s Hospital Medical Center is conducting a research study, sometimes known as a clinical trial or clinical study, to test how safe and well tolerated the study drug is in children and young adults with certain cancers. Researchers want to see what effects - good or bad - the stu...
More
